600285 羚锐制药
2023/09 - 九个月2022/122021/122020/122019/12

盈利能力分析
净资产收益率 ROE (%)17.71919.26915.74814.39013.720
总资产报酬率 ROA (%)10.38711.4379.9729.6119.164
投入资产回报率 ROIC (%)16.22817.40414.64413.17812.597

边际利润分析
销售毛利率 (%)74.62772.28074.27276.90877.287
营业利润率 (%)21.50617.22716.15015.74415.829
息税前利润/营业总收入 (%)20.48116.33814.96314.96515.724
净利润/营业总收入 (%)18.59715.50113.45813.91313.590

收益指标分析
经营活动净收益/利润总额(%)96.41080.73896.01491.64698.357
价值变动净收益/利润总额(%)2.01412.4917.40311.300-2.929
营业外收支净额/利润总额(%)-0.227-0.017-5.240-0.794-0.048

偿债能力分析
流动比率 (X)1.3311.4651.4821.7971.730
速动比率 (X)1.0831.1811.1841.4871.448
资产负债率 (%)41.30641.10939.71732.84233.034
带息债务/全部投入资本 (%)4.2657.4156.540--3.372
股东权益/带息债务 (%)2,184.0271,213.3841,387.1045,320.4492,763.636
股东权益/负债合计 (%)141.696142.835151.276203.656201.755
利息保障倍数 (X)-20.993-18.446-39.001-22.819-161.171

营运能力分析
应收账款周转天数 (天)26.43222.11921.2930.00029.974
存货周转天数 (天)199.732197.887197.3530.000224.293